Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois, Jérôme Eeckhoute, Philippe Lefèbvre et al. · Journal of Clinical Investigation · 2017
Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
Cited by 383 works. doi:10.1172/jci88894 Open-access PDF
Authors
References
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
- A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
- Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ